VMA21 activators comprise a series of chemical entities that are involved in the upregulation or enhancement of the activity of the VMA21 protein. VMA21 is a chaperone protein essential for the assembly of V0, the membrane-integrating sector of the vacuolar-type H+-ATPase (V-ATPase) complex. V-ATPases are proton pumps that acidify intracellular compartments, playing a pivotal role in processes such as protein sorting, zymogen activation, and the coupling of proton flow to ATP synthesis. The VMA21 protein itself does not form part of the V-ATPase complex but is crucial for its assembly; without VMA21, the V-ATPase complex would not form properly, leading to a deficiency in the acidification process that is fundamental for various cellular activities.
Activators of VMA21 function to increase the stability or expression of the VMA21 protein, thereby potentially enhancing the efficiency of V-ATPase complex assembly. Such activators may interact directly with VMA21, stabilizing the protein and protecting it from degradation, or they may interact indirectly by upregulating the transcription of the VMA21 gene, leading to an increased production of the protein. The interaction between VMA21 activators and their target can influence the proper folding and maturation of the V0 sector subunits, ensuring their correct incorporation into the V-ATPase complex. By fostering the assembly of V-ATPase, VMA21 activators indirectly support the cellular processes that rely on the acidification of intracellular compartments.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
DCC | 538-75-0 | sc-239713 sc-239713A | 25 g 100 g | $72.00 $208.00 | 3 | |
Affect V-ATPase by covalently modifying a conserved glutamic acid; could indirectly modulate VMA21 roles. | ||||||
Vacuolin-1 | 351986-85-1 | sc-216045 | 10 mg | $265.00 | 29 | |
Affects lysosomal morphology and inhibits lysosomal acidification, indirectly involving V-ATPase and possibly VMA21. | ||||||
FCCP | 370-86-5 | sc-203578 sc-203578A | 10 mg 50 mg | $94.00 $355.00 | 46 | |
Disrupts proton gradients; its actions can indirectly involve VMA21 in V-ATPase regulation. | ||||||
Nigericin sodium salt | 28643-80-3 | sc-201518A sc-201518 sc-201518B sc-201518C sc-201518D | 1 mg 5 mg 25 mg 1 g 5 g | $46.00 $112.00 $240.00 $7079.00 $27417.00 | 9 | |
K+/H+ ionophore that disrupts pH gradients; its presence can involve VMA21 indirectly via V-ATPase modulation. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Another ionophore impacting pH gradients; might affect V-ATPase complex indirectly involving VMA21. | ||||||
Clomiphene Citrate | 50-41-9 | sc-205636 sc-205636A | 1 g 5 g | $84.00 $176.00 | 1 | |
Has been shown to affect lysosomal acidification; could potentially influence VMA21 via V-ATPase pathways. | ||||||
Lansoprazole | 103577-45-3 | sc-203101 sc-203101A | 500 mg 1 g | $59.00 $176.00 | 6 | |
Another proton pump inhibitor; similar to Omeprazole, can have an indirect effect on VMA21 and V-ATPase. | ||||||